Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Bone Drugs Linked to Esophageal Cancer in New Study

Filed May 31st, 2012 Laurie

Bisphosphonate bone drugs may pose a bigger esophageal cancer risk than previously thought – especially the drug Fosamax, according to an adverse event surveillance study. Beatrice J. Edwards, MD, of Northwestern University in Chicago, and colleagues carried out the study.

The Food and Drug Administration received 128 reports of bisphosphonate-associated esophageal cancer to its adverse events reporting system from 1995 to 2010. That risk appeared disproportionate with alendronate, the group reported in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago taking place this week.

Alendronate accounted for 75 percent of the esophageal cancers seen with bisphosphonates in the FDA database. Alendronate likewise had an empiric Bayes geometric mean of 6.3, suggesting that the esophageal cancer cases were more common with bisphosphonates than with other drugs in the database.

The esophageal cancer events they found associated with bisphosphonate use were 96 cases with alendronate, 14 with risedronate, 10 with ibandronate, seven with zoledronic acid, and one with pamidronate (Aredia).

There were three reports of Barrett’s esophagus, which led researchers to recommend that patients with the cancer risk and patients with persistent mucosal abnormalities avoid taking oral bisphosphonates.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!